Literature DB >> 20870723

Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.

Ruiyi Ren1, Zhenning Hong, Haiyan Gong, Kate Laporte, Martha Skinner, David C Seldin, Catherine E Costello, Lawreen H Connors, Vickery Trinkaus-Randall.   

Abstract

Primary amyloidosis (AL) results from overproduction of unstable monoclonal immunoglobulin light chains (LCs) and the deposition of insoluble fibrils in tissues, leading to fatal organ disease. Glycosaminoglycans (GAGs) are associated with AL fibrils and have been successfully targeted in the treatment of other forms of amyloidosis. We investigated the role of GAGs in LC fibrillogenesis. Ex vivo tissue amyloid fibrils were extracted and examined for structure and associated GAGs. The GAGs were detected along the length of the fibril strand, and the periodicity of heparan sulfate (HS) along the LC fibrils generated in vitro was similar to that of the ex vivo fibrils. To examine the role of sulfated GAGs on AL oligomer and fibril formation in vitro, a κ1 LC purified from urine of a patient with AL amyloidosis was incubated in the presence or absence of GAGs. The fibrils generated in vitro at physiologic concentration, temperature, and pH shared morphologic characteristics with the ex vivo κ1 amyloid fibrils. The presence of HS and over-O-sulfated-heparin enhanced the formation of oligomers and fibrils with HS promoting the most rapid transition. In contrast, GAGs did not enhance fibril formation of a non-amyloidogenic κ1 LC purified from urine of a patient with multiple myeloma. The data indicate that the characteristics of the full-length κ1 amyloidogenic LC, containing post-translational modifications, possess key elements that influence interactions of the LC with HS. These findings highlight the importance of the variable and constant LC regions in GAG interaction and suggest potential therapeutic targets for treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870723      PMCID: PMC2988372          DOI: 10.1074/jbc.M110.149575

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Immunoglobulin light chains, glycosaminoglycans, and amyloid.

Authors:  F J Stevens; R Kisilevsky
Journal:  Cell Mol Life Sci       Date:  2000-03       Impact factor: 9.261

2.  Surface-catalyzed amyloid fibril formation.

Authors:  Min Zhu; Pierre O Souillac; Cristian Ionescu-Zanetti; Sue A Carter; Anthony L Fink
Journal:  J Biol Chem       Date:  2002-09-27       Impact factor: 5.157

3.  Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN.

Authors:  Pierre O Souillac; Vladimir N Uversky; Anthony L Fink
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

4.  A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy.

Authors:  Ritu Khurana; Cristian Ionescu-Zanetti; Maighdlin Pope; Jie Li; Liza Nielson; Marina Ramírez-Alvarado; Lynn Regan; Anthony L Fink; Sue A Carter
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

5.  The amyloid fibrils of the constant domain of immunoglobulin light chain.

Authors:  Kaori Yamamoto; Hisashi Yagi; Young-Ho Lee; József Kardos; Yoshihisa Hagihara; Hironobu Naiki; Yuji Goto
Journal:  FEBS Lett       Date:  2010-06-18       Impact factor: 4.124

6.  Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.

Authors:  A Lim; J Wally; M T Walsh; M Skinner; C E Costello
Journal:  Anal Biochem       Date:  2001-08-01       Impact factor: 3.365

7.  Extended N-sulfated domains reside at the nonreducing end of heparan sulfate chains.

Authors:  Gregory O Staples; Xiaofeng Shi; Joseph Zaia
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

8.  Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.

Authors:  Jeffrey A Cohlberg; Jie Li; Vladimir N Uversky; Anthony L Fink
Journal:  Biochemistry       Date:  2002-02-05       Impact factor: 3.162

Review 9.  Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit.

Authors:  John B Ancsin
Journal:  Amyloid       Date:  2003-06       Impact factor: 7.141

10.  Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH.

Authors:  Suguru Yamamoto; Itaru Yamaguchi; Kazuhiro Hasegawa; Shinobu Tsutsumi; Yuji Goto; Fumitake Gejyo; Hironobu Naiki
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

View more
  23 in total

Review 1.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

2.  In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Sallie Macy; Emily B Martin; Angela Williams; Keiichi Higuchi; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

3.  Critical Influence of Cosolutes and Surfaces on the Assembly of Serpin-Derived Amyloid Fibrils.

Authors:  Michael W Risør; Dennis W Juhl; Morten Bjerring; Joachim Mathiesen; Jan J Enghild; Niels C Nielsen; Daniel E Otzen
Journal:  Biophys J       Date:  2017-08-08       Impact factor: 4.033

Review 4.  Current perspectives on cardiac amyloidosis.

Authors:  Jian Guan; Shikha Mishra; Rodney H Falk; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

5.  Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Biophys Chem       Date:  2011-05-18       Impact factor: 2.352

6.  Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains.

Authors:  Pinaki Misra; Luis M Blancas-Mejia; Marina Ramirez-Alvarado
Journal:  Biochemistry       Date:  2019-07-09       Impact factor: 3.162

7.  Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.

Authors:  Luis M Blancas-Mejía; Jared Hammernik; Marta Marin-Argany; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

8.  The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.

Authors:  Gareth J Morgan; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2016-08-26       Impact factor: 5.469

Review 9.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

10.  Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A.

Authors:  J Javier Aguilera; Fuming Zhang; Julie M Beaudet; Robert J Linhardt; Wilfredo Colón
Journal:  Biochimie       Date:  2014-05-28       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.